Company / Operating Income
Stoke Therapeutics, Inc. Operating Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$20.6M
FY2025
5-year range
-$114.8M / -$20.6M
FY2021-FY2025
Trend
+82.1%
vs FY2024
Sector context
#63 of 204
Health Care
What the data says
At -$21M, Stoke Therapeutics, Inc.'s operating income ranks #63 of 204 in the Health Care sector. Operating Income returned to growth in FY2025 after 2 years of decline, reaching -$21M.
Based on SEC 10-K filings.
-$21M in FY2025.
Improved from -$104M to -$21M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#63 of 204 in Health CareTop 31% of 204This company -$20.6M Sector average $107.7M
▼
-119.1% below sector average
Key checks
Key Insights
- In FY2025, operating income increased 82.1% year-over-year.
- Ranks #63 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2018.
- Lowest operating income in the period was in FY2024.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$20.6M | +82.1% |
| FY2024 | -$114.8M | -10.0% |
| FY2023 | -$104.4M | -21.3% |
| FY2022 | -$86.1M | +0.0% |
| FY2021 | -$86.1M | -62.3% |
| FY2020 | -$53.0M | -48.7% |
| FY2019 | -$35.7M | -179.1% |
| FY2018 | -$12.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026